SC
FOLD

Stephens Consulting’s Amicus Therapeutics FOLD Stock Holding History

Stephens Consulting’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-90
Closed -$735 – 1478
2025
Q1 		$735 Buy
+90
New +$833 ﹤0.01% 793
2024
Q3 		– Sell
-189
Closed -$1.88K – 570
2024
Q2 		$1.88K Buy
+189
New +$1.94K ﹤0.01% 520

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stephens Consulting's FOLD Position: Q2 2025 in Review

Stephens Consulting sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 90 shares — an estimated $735 sold.

Stephens Consulting first reported a position in FOLD in Q2 2024 and held it in 2 quarters. The position peaked at $1.88K in Q2 2024. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Stephens Consulting reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 90 Amicus Therapeutics shares in Q2 2025, an estimated $735.
  • Stephens Consulting first reported a position in Amicus Therapeutics in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Amicus Therapeutics position peaked at $1.88K in Q2 2024.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.